Capsule structure with a red yeast compound

Abstract

Capsule structure (C) with a red yeast compound, comprising: - a capsule body (10) comprising a first capsule shell (11) and a second capsule shell (12), wherein the first capsule shell (11) and the second capsule shell (12) are placed on top of each other in such a way that they together enclose a closed receiving space (13); and - several functional particles (20) arranged in the receiving space (13) of the capsule body (10), wherein the composition of the functional particles (20) includes red yeast (21), nattokinase (22) and coenzyme Q10 (23).

Description

[0001] The present utility model relates to a capsule structure, in particular to a capsule structure with a red yeast compound.

[0002] Nowadays, the selection of foods is diverse and demanding. In addition, modern people tend to eat a high-fat diet and often have poor lifestyle habits, such as lack of exercise, which leads to poor metabolism of body fat. As a result, approximately 20% of the country's population suffers from dyslipidemia.

[0003] Lipids are the abbreviation for fats in blood serum, which mainly consist of triglycerides and cholesterol. High triglycerides, high total cholesterol, low high-density lipoprotein cholesterol (HDL-C), or high low-density lipoprotein cholesterol (LDL-C) in the blood are referred to as dyslipidemia or hyperlipidemia.

[0004] Prolonged abnormal blood lipid levels can easily lead to high blood pressure and arteriosclerosis, which in turn increase the risk of arterial blockage and can thus lead to heart attack, angina pectoris, or stroke. Therefore, the question of how to improve the phenomenon of abnormal blood lipids through the consumption of healthy foods, in order to support the reduction of blood lipids in the human body, has become an important issue that needs to be addressed in this technical field.

[0005] Based on the disadvantages of the prior art, the present utility model aims to offer a capsule structure containing a red yeast compound. The capsule structure containing a red yeast compound according to the present utility model can effectively prevent or improve high blood lipids, high body fat, and / or high cholesterol.

[0006] To solve this problem, the present utility model proposes a capsule structure containing a red yeast compound, comprising a capsule body and several functional particles. The capsule body has a first capsule shell and a second capsule shell, the first and second capsule shells being stacked on top of each other to jointly enclose a sealed receiving space. The functional particles are arranged within this receiving space of the capsule body. The composition of the functional particles includes red yeast, nattokinase, and coenzyme Q10.

[0007] In one embodiment of the present utility model, the first capsule shell has a first closed end and a first contact end opposite the first closed end, and the second capsule shell has a second closed end and a second contact end opposite the second closed end, wherein the outer diameter of the second contact end corresponds to the inner diameter of the first contact end of the first capsule shell, so that the second capsule shell snaps into the first capsule shell.

[0008] In one embodiment of the present utility model, it is provided that the content of red yeast is 187.5 mg to 375 mg, the fibrinolytic units of nattokinase are 2500 FU to 5000 FU, and the content of coenzyme Q10 is 15 mg to 30 mg.

[0009] In one embodiment of the present utility model, the red yeast contains monacolin K.

[0010] In one embodiment of the present utility model, the capsule body is a plant-based capsule.

[0011] One of the advantageous effects of the present utility model is that the capsule structure with a red yeast compound according to the present utility model, through the technical solutions "the first capsule shell and the second capsule shell are placed on top of each other in such a way that they together enclose a closed receiving space" and "several functional particles are arranged in the receiving space of the capsule body, wherein the composition of the several functional particles includes red yeast, nattokinase and coenzyme Q10", can effectively promote metabolism and regulate physiological functions in order to effectively prevent or improve high blood lipids, high body fat and / or high cholesterol.

[0012] For a better understanding of the features and technical content of the present utility model, reference is made to the following detailed description and the drawings of the present utility model, which, however, serve only for illustration and are not intended to restrict the present utility model. Fig. Figure 1 shows a schematic three-dimensional external view of a capsule structure of a second embodiment of the present utility model. Fig. Figure 2 shows a schematic three-dimensional exploded view of a capsule body of the second embodiment of the present utility model. Fig. Figure 3 shows a schematic three-dimensional perspective view of the capsule structure of the second embodiment of the present utility model. Fig. Figure 4 shows a composition diagram of the functional particles according to an embodiment of the present utility model.

[0013] The following describes, with reference to specific embodiments, the embodiments of a capsule structure containing a red yeast compound, disclosed within the scope of this utility model. Those skilled in the art will recognize that the advantages and technical effects of this utility model can be derived from the disclosures in this description. This utility model can be implemented or applied through other specific embodiments, whereby various modifications or alterations can be made to the details disclosed in this description, depending on requirements and application, without departing from the fundamental ideas of this utility model. Furthermore, it should be noted that the individual components of this utility model are not shown in their actual size, but only schematically.The following embodiments serve to further describe the configurations of the present utility model, but the corresponding disclosures do not constitute a limitation of the scope of protection of the present utility model. Furthermore, the term "or" used in this description may, where appropriate, encompass any of the items listed or a combination of several such items. [First embodiment]

[0014] The first embodiment of the present utility model provides a composition to support lipid reduction (e.g., to reduce high blood lipids, high cholesterol, or body fat) which contains, among other things, red yeast, nattokinase, and coenzyme Q10. In an effective dose of the composition, red yeast is present in an amount of 187.5 mg to 375 mg, nattokinase in an amount of 2500 FU to 5000 FU (fibrinolytic units), and coenzyme Q10 in an amount of 15 mg to 30 mg.

[0015] In the present embodiment, the red yeast content in an effective dose of the composition is 187.5 mg to 375 mg. It is worth noting that the active ingredient of the red yeast is monacolin K, which can contribute to lowering lipids. In some other embodiments, the red yeast content can also be 180 mg, 182.5 mg, 185 mg, 187.5 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, or 375 mg. However, the present utility model is not limited to the examples mentioned above.

[0016] Natto is a highly nutritious ingredient obtained by fermenting soybeans with Bacillus subtilis. However, natto has a rather strong odor and high viscosity, which is not acceptable to everyone. Therefore, in this utility model, the active ingredient nattokinase is extracted from natto. Nattokinase is a serine protease obtained after purification and extraction, and its effects on promoting metabolism and regulating physiological functions have been confirmed by research. The activity of nattokinase is measured in fibrinolytic units (FU). In the present embodiment, the fibrinolytic units of nattokinase range between 2500 FU and 5000 FU in an effective dose of the composition. However, this utility model is not limited to the example mentioned above.

[0017] Currently, coenzyme Q10 is known as an antioxidant and an important coenzyme for energy and metabolism, and it has the function of preventing cancer, counteracting aging, and improving cardiomyopathy. In the present embodiment, the coenzyme Q10 content in an effective dose of the composition is 15 mg to 30 mg. However, this utility model is not limited to the example mentioned above. [Second embodiment]

[0018] As in Fig. As shown in Figures 1 to 3, the second embodiment of the present utility model provides a capsule structure C with a red yeast compound comprising a capsule body 10 and several functional particles 20.

[0019] The capsule body 10 comprises a first capsule shell 11 and a second capsule shell 12, wherein the first capsule shell 11 and the second capsule shell 12 are positioned one on top of the other in such a way that they together enclose a closed receiving space 13. The functional particles 20 are arranged in the receiving space 13 of the capsule body 10. However, the present utility model is not limited to the example mentioned above.

[0020] Specifically, the first capsule shell 11 has a first closed end 111 and a first contact end 112 opposite the first closed end 111, and the second capsule shell 12 has a second closed end 121 and a second contact end 122 opposite the second closed end 121, wherein the outer diameter of the second contact end 122 corresponds to the inner diameter of the first contact end 112 of the first capsule shell 11, so that the second capsule shell 12 can snap into the first capsule shell 11 to create the closed receiving space 13 for receiving the functional particles 20. The functional particles 20 can be in the form of powder particles, granules, or powders.

[0021] As in Fig.As shown in Figure 4, the multiple functional particles 20 of the present embodiment are the lipid-lowering composition from the first embodiment. In other words, the composition of the multiple functional particles 20 comprises at least red yeast 21, nattokinase 22, and coenzyme Q10 23; that is, the composition of the functional particles 20 is a red yeast compound. In an effective dose of the composition, red yeast 21 is present in an amount of 187.5 mg to 375 mg, nattokinase 22 in an amount of 2500 FU to 5000 FU (fibrinolytic units), and coenzyme Q10 in an amount of 15 mg to 30 mg. However, the present utility model is not limited to the examples mentioned above.

[0022] It should be noted that the receiving chamber 13 of the capsule body 10 can provide a good preservation environment for the functional particles 20. When the multiple functional particles 20 are hermetically packaged in the receiving chamber 13, it can be filled with dry air to make the functional particles 20 less susceptible to deterioration. However, the example given above represents only one possible embodiment and is not intended to limit the present utility model.

[0023] In the present embodiment, the capsule body 10 can be a plant-based capsule whose material contains hydroxypropylmethylcellulose, purified water, carrageenan and potassium chloride. [Third embodiment]

[0024] In the present embodiment, another man with hyperlipidemia was administered capsule structure C of the second embodiment of the present utility model, two capsules per day. It should be noted that in the present embodiment, the composition of the functional particles comprises red yeast, nattokinase, and coenzyme Q10. Each capsule structure C contains 187.5 mg of red yeast, 2500 FU (fibrinolytic units) of nattokinase, and 15 mg of coenzyme Q10. After daily intake of two capsule structures C, the man's hyperlipidemia and high body fat improved by day 30. [Advantageous effects of the exemplary embodiments]

[0025] One of the advantageous effects of the present utility model is that the capsule structure with a red yeast compound according to the present utility model, through the technical solutions "the first capsule shell and the second capsule shell are placed on top of each other in such a way that they together enclose a closed receiving space" and "several functional particles are arranged in the receiving space of the capsule body, wherein the composition of the several functional particles comprises red yeast, nattokinase and coenzyme Q10", can effectively promote metabolism and regulate physiological functions in order to effectively prevent or improve high blood lipids, high body fat and / or high cholesterol.

[0026] Furthermore, in the capsule structure with a red yeast compound according to the present utility model, an effective reduction of high blood lipids, high body fat and / or high cholesterol can be achieved synergistically through the combined use of red yeast, nattokinase and coenzyme Q10.

[0027] The above disclosure merely presents preferred possible embodiments of the present utility model and is not intended to limit the claims of the present utility model, so that all equivalent technical modifications made by applying the content of the description and the drawings of the present utility model are included in the claims of the present utility model. Reference symbol list C Capsule structure 10 capsule bodies 11 First capsule shell 111 First closed end 112 First touchdown 12 Second capsule shell 121 Second closed end 122 Second touchdown 13 Recording Room 20 Functional Particles 21 Red Yeast 22 Nattokinase 23 Coenzyme Q10

Claims

[1] Capsule structure (C) with a red yeast compound, comprising: - a capsule body (10) comprising a first capsule shell (11) and a second capsule shell (12), wherein the first capsule shell (11) and the second capsule shell (12) are placed on top of each other in such a way that they together enclose a closed receiving space (13); and - several functional particles (20) arranged in the receiving space (13) of the capsule body (10), wherein the composition of the functional particles (20) includes red yeast (21), nattokinase (22) and coenzyme Q10 (23). [2] Capsule structure (C) comprising a red yeast compound according to claim 1, wherein the first capsule shell (11) has a first closed end (111) and a first contact end (112) opposite the first closed end (111) and the second capsule shell (12) has a second closed end (121) and a second contact end (122) opposite the second closed end (121), wherein the outer diameter of the second contact end (122) corresponds to the inner diameter of the first contact end (112) of the first capsule shell (11), such that the second capsule shell (12) snaps into the first capsule shell (11). [3] Capsule structure (C) comprising a red yeast compound according to any of the preceding claims, wherein the red yeast content (21) is 187.5 mg to 375 mg, the fibrinolytic units of nattokinase (22) are 2500 FU to 5000 FU and the coenzyme Q10 content (23) is 15 mg to 30 mg. [4] Capsule structure (C) with a red yeast compound according to any of the preceding claims, wherein the red yeast (21) contains monacolin K. [5] Capsule structure (C) comprising a red yeast compound according to any one of the preceding claims, wherein the capsule body (10) is a plant-based capsule.

Images